| Similar Articles |
|---|
 |
Bio-IT World
April 2006
Laura Huckabee-Jennings |
Southern Emergence Why Huntsville, Alabama, will be the next biotech hotbed.   |
IndustryWeek
November 1, 2002
Tonya Vinas |
Questioning Biotech's Benefits While most communities are investing to attract or grow biotechnology companies, a recent report concludes that only a handful of cities will benefit in the long run. |
Bio-IT World
June 15, 2003
Bob Violino |
Northeast Region Massachusetts: University and Research Hub... Connecticut: Investing in Bio Facilities... New York: Biotech Empire State... New Jersey: Still Big Pharma Country... Pennsylvania: Life Sciences, a Keystone Industry |
BusinessWeek
November 10, 2003
Arlene Weintraub |
Biotech Startups: Take Your Time Until products are close to approval, the public shouldn't share the risk |
BusinessWeek
June 13, 2005 |
Biotech's "Fantastic Future Ahead" Some bold predictions on what's coming for the biotech industry from Ernst & Young's Scott Morrison. |
Bio-IT World
July 14, 2004 |
Not Just a Day at the Beach Joseph Panetta recalls leaving the comfort of a pharma job in Philadelphia for a position in biotech in San Diego, whose fledgling biotech community survived stormy nascent years to mushroom into a biotech hotbed. |
Bio-IT World
June 15, 2003
Bob Violino |
Mid-Atlantic/Southeast Region Maryland: Making a Federal Case for Biotechnology... Puerto Rico: Isle of Incentives... Virginia: Planting Needed Seed Capital... North Carolina: Triangulating Biotech Resources... Florida: Shining Resources on Small Biotech Sector |
Job Journal
September 21, 2003
Marty Nemko |
Biotech = Opportunity What this strong growth industry could offer you |
National Real Estate Investor
June 1, 2003
H. Lee Murphy |
Who's Behind Biotech? There is a niche in the office market where vacancies are a fraction of the national rate, rents are way above average, and prospects for growth actually exist. It is the specialized (and regionally concentrated) business of supplying space to the biotech and life sciences industry. |
Managed Care
May 2004 |
Biologics Among Fastest Growers Managed care plans and pharmacy benefit managers can benefit from the strong generic presence in the market, but also face challenges relating to biotech drugs. |
The Motley Fool
April 4, 2005
John Reeves |
Returns That Defy the Imagination Want to save lives while pursuing a high-growth investment strategy? Try exploring the biotech frontier. |
The Motley Fool
April 4, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Exchange-traded funds don't work for this industry. |
BusinessWeek
March 7, 2005
Arlene Weintraub |
Where VCs Fear To Tread Angel investors are filling a critical gap by providing early backing for biotechs. |
Bio-IT World
June 15, 2003
Barbara Depompa |
Northwest Region Colorado: Biotech Summit in Denver... Utah: A Mecca for Genealogical Research... Washington State: Therapeutics and Diagnostics Niche... |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
Pharmaceutical Executive
November 1, 2011 |
Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk. |
The Motley Fool
August 13, 2007
Andrew R. Vaino |
Do You See What I WuXi? This Chinese biotech outsourcing firm recently went public and has lots of room to grow. |
Bio-IT World
July 11, 2002
Mike Fitzgerald |
Funding the Future Investor G. Steven Burrill, CEO of Burrill & Company, helps biotech companies fulfill their potential. He talked recently about his view of the bio-IT field. |
Bio-IT World
October 14, 2004
Robinson & Violino |
Strategic Insights: Global Positioning International Economic Development for biotech companies in search of a better location or international presence, countries in Asia and Europe are offering a host of incentives, including tax credits and reduced red tape. |
The Motley Fool
February 23, 2005
Brian Gorman |
Amgen Gets Disciplined Direct-to-consumer advertising may be a non-starter for Amgen and other biotech companies. |
The Motley Fool
May 5, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Persuading you to invest in biotechs should be easy. Persuading you not to use what seems like a less-risky strategy might be harder. Exchange-traded funds just don't work for this industry. |
National Real Estate Investor
May 1, 2006
F. R. Skinner |
Bulking Up On Biotech Investing in the development of a highly unique, medical-grade building is only going to appeal to a select niche of investors. But with biotech returns averaging some 1% to 2% higher than the general office market, it is a smart play for investors wanting a diversified portfolio. |
The Motley Fool
July 22, 2004
Brian Gorman |
Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent. |
The Motley Fool
November 16, 2006
Jim Fink |
The Best ETF for 2007: H&Q Life Sciences Investors H&Q Life Sciences, a health-care fund investing in one of the highest-growth sectors of the U.S. economy, is trading at a discount to NAV. Consequently, it's now primed to be the best-performing ETF for 2007. |
The Motley Fool
May 20, 2011
Selena Maranjian |
Beware These "Very Attractive" ETFs There are some big red flags here. |
Chemistry World
June 29, 2009
Anna Lewcock |
Going green with white biotech Industrial biotech has also been growing steadily in the chemicals sector, and in 2007 six per cent of all chemical sales were generated with the help of enzymes - so-called 'white' biotech. |
The Motley Fool
May 5, 2004
Brian Gorman |
Albany Molecular Gets Out-Outsourced Albany Molecular Research, provider of chemistry services to biotech and pharmaceutical clients, is suffering from the loss of business to low-cost competitors overseas. |
Job Journal
July 16, 2006
Julia Hollister |
Biotech Boom The biotech field offers promising jobs in a profession that's expanding faster than you can spell biotherapeutics. |
Knowledge@Wharton
October 8, 2003 |
Biosciences: High Risk, High Reward, and the Potential for "Real Chaos" While bioscience researchers struggle to understand the workings of the human body, biotech managers and investors are searching for ways to better understand this complex and quickly evolving industry, according to Wharton faculty and lecturers. |
Pharmaceutical Executive
May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short. |
The Motley Fool
January 4, 2007
Ralph Casale |
Picks and Shovels of Biotechnology Biotech investors will continue to venture into the dark mines of burgeoning pharmaceutical firms. There is certainly gold to be found in some of them, just remember to invest in some of the hardware stores of biotechnology along the way. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances. |
HBS Working Knowledge
November 13, 2006
Sean Silverthorne |
Science Business: What Happened to Biotech? The biotech industry has underperformed expectations, caught in the conflicting objectives and requirements between science and business. |
Job Journal
August 8, 2004
Rich Heintz |
Biotech's Winning Formula for Steady Job Growth Deep pockets are creating expanding opportunities and biotechnology is helping to put America back to work. |
Chemistry World
April 21, 2009
Matt Wilkinson |
Survival of the fittest While the pharmaceutical and biopharmaceutical sectors in general are outperforming broader stock market trends, many early stage companies are desperately trying to conserve cash and raise money to keep going. |
Entrepreneur
June 2005
Rieva Lesonsky |
A Group of Greats Entrepreneurs comprise an incredible, diverse community. |
Bio-IT World
June 15, 2003
Barbara Depompa |
Southwest Region Texas: Bioscience with a Space Spin... New Mexico: Building a Bioinformatics Niche... Arizona: Focus on Cancer and Neurological Therapy... Southern California: Deep Biotech Roots Grow Many Branches... Northern California: 'Can You Afford To Be Elsewhere?'... |
BusinessWeek
March 26, 2007
Arlene Weintraub |
Biotech's Unlikely New Pal Can private equity manage its big risks and far-off returns? |
Knowledge@Wharton
March 26, 2003 |
Health Care Finance Industry Plagued by Lack of Funding, Focus In today's health care finance environment, early financing rounds are harder to fund and the market for initial public financings is dead, with no revival expected anytime soon. |
The Motley Fool
October 23, 2006
Jack Uldrich |
Is Microsoft on Drugs? If the company uses its new BioIT Alliance not simply to push its existing software, but also to better understand what biotech customers need and want, Microsoft's new drug habit could even provide its long-suffering shareholders a little high. |
The Motley Fool
January 25, 2005
Charly Travers |
Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs. |
The Motley Fool
May 19, 2004
Roger Nusbaum |
Gilead Shines This biotech company looks strong because investors can relate to its products. |
| Knowledge@Wharton |
The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope... |
